VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | CTC whole-genome sequencing vs FISH to monitor the emergence of multiple myeloma high-risk subclones

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of using whole-genome sequencing (WGS) of circulating tumor cells (CTCs) to detect the emergence of high-risk genetic subclones in patients with multiple myeloma. Dr Ghobrial explains that CTCs can be used as a prognostic marker as well as to monitor disease progression and tailor therapy, and argues that this technology could replace standard molecular cytogenetics techniques such as FISH. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter